ASCO 2025: New Standards Reshape Care in mBC
Heather McArthur, MD, describes how the 2025 ASCO Annual Meeting brought exciting advances in the metastatic breast cancer space. In PD-L1-positive triple-negative breast cancer, sacituzumab govitecan combined with pembrolizumab significantly improved progression-free survival over standard chemotherapy plus pembrolizumab, quickly becoming a new standard of care.
Similarly, in HER2-positive disease, trastuzumab deruxtecan combined with pertuzumab outperformed traditional THP therapy, offering a new frontline option. Overall, these findings signify a major shift in how to treat metastatic breast cancer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
15 minutes ago
- Bloomberg
Trump Administration's New Rule Will Limit Obamacare Enrollments
Trump administration officials on Friday finalized regulations aimed at making it more difficult to enroll in health insurance through the Affordable Care Act. The rules will limit the time frame for people to sign up for health insurance through the exchanges and cancel a monthly opportunity for people with incomes below 150% of the federal poverty line to enroll, among other changes.
Medscape
20 minutes ago
- Medscape
Updates in Metastatic NSCLC From ASCO 2025
Dr Jonathan Goldman, of the University of California, Los Angeles, shares key updates in metastatic non-small cell lung cancer from ASCO 2025. Dr Goldman reviews findings from TROPION-Lung02, which evaluated datopotamab deruxtecan (Dato-DXd) ± pembrolizumab (pembro) in first-line metastatic NSCLC. The objective response rate (ORR) was 55% for Dato-DXd + pembro vs 56% for chemo. Improved outcomes in TROP2 NMR-positive patients may indicate a predictive biomarker. Dr Goldman then discusses results from OptiTROP-Lung03, in which sacituzumab tirumotecan (sac-TMT) showed superior efficacy compared to docetaxel in pretreated EGFR-mutated NSCLC. The ORR for sac-TMT was 45% vs 15% for docetaxel. Next, he highlights updates from KRYSTAL-7 of first-line adagrasib plus pembro in KRASG12C-mutant NSCLC. The combination yielded an ORR of 44% and median duration of response of 26.3 months. In patients with a PD-L1 ≥ 50%, ORR reached 50% vs 34% in those with lower expression. Dr Goldman also reports on HERTHENA-Lung02, in which patritumab deruxtecan (HER3-DXd) improved progression-free survival (PFS) vs chemo in resistant EGFR-mutated NSCLC, but the lack of overall survival benefit led to application withdrawal. Finally, Dr Goldman reviews phase 2b findings from REZILIENT1, evaluating zipalertinib in EGFR exon 20-mutant NSCLC. In patients without prior amivantamab, ORR was 40% and PFS was 9.5 months. In those previously treated with amivantamab, zipalertinib resulted in clinically meaningful results: an ORR of 23.5% and PFS of 7.3 months.
Fox News
26 minutes ago
- Fox News
Vaccines and Sardines and MAHA, Oh My! Dr. Nicole Saphier Joins the Guy Benson Show
Dr. Nicole Saphier, board-certified medical doctor, senior Fox News medical contributor, and bestselling author of Panic Attack: Playing Politics with Science in the Fight Against COVID-19 , joined The Guy Benson Show today to weigh in on RFK Jr.'s shake-up of his vaccine advisory committee, some of whose ties date back to the COVID era. Saphier offered her take on the changes, saying she might've gone further by stripping questionable financial connections instead of firing all of the members outright. She also reacted to the bizarre but booming 'sardine girl summer' health trend that's taking social media by storm, and you can listen to the full interview below! Listen to the full interview below: Listen to the full podcast below:
